OptimizeRx (OPRX) Scheduled to Post Quarterly Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) will be releasing its earnings data after the market closes on Wednesday, November 13th. Analysts expect OptimizeRx to post earnings of $0.06 per share for the quarter. OptimizeRx has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The company had revenue of $18.81 million for the quarter, compared to the consensus estimate of $20.47 million. OptimizeRx had a negative net margin of 21.53% and a negative return on equity of 5.97%. On average, analysts expect OptimizeRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $5.11 on Wednesday. The company has a market cap of $93.63 million, a P/E ratio of -5.11 and a beta of 1.32. The firm has a fifty day moving average price of $6.98 and a 200 day moving average price of $9.20. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.27. OptimizeRx has a 12 month low of $5.04 and a 12 month high of $16.65.

Analysts Set New Price Targets

OPRX has been the subject of several recent analyst reports. B. Riley began coverage on OptimizeRx in a research note on Thursday, July 25th. They set a “buy” rating and a $18.50 target price for the company. Royal Bank of Canada cut their price objective on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. Finally, Barclays dropped their target price on shares of OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.